Oryzon names Greg Weaver CFO
This article was originally published in Scrip
Executive Summary
Oryzon Genomics, a clinical stage biopharmaceutical company developing therapeutics in oncology and CNS diseases, has appointed Gregory L Weaver as executive vice-president and chief financial officer – effective 12 January 2015. Mr Weaver has served as CFO of several public biotech companies in the US, most recently Fibrocell Science. At Oryzon, he will report directly to Carlos Buesa, president and CEO of Oryzon, and will be based at the firm's US headquarters located in Cambridge, Massachusetts.